Literature DB >> 11886533

Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis.

N Kanda1, U Enomoto, S Watanabe.   

Abstract

It is reported that anti-mycotic agents are effective for the treatment of patients with atopic dermatitis. We studied the in vitro effects of anti-mycotics on T helper-1 and T helper-2 cytokine production in anti-CD3 plus anti-CD28-stimulated T cells from atopic dermatitis patients and normal donors. The amounts of interleukin-4 and interleukin-5 secreted by anti-CD3/CD28-stimulated T cells were higher in atopic dermatitis patients than in normal donors. Azole derivatives, ketoconazole, itraconazole, miconazole, and nonazole terbinafine hydrochloride, and tolnaftate reduced interleukin-4 and interleukin-5 secretion without altering that of interferon-gamma and interleukin-2 in anti-CD3/CD28-stimulated T cells from both atopic dermatitis patients and normal donors. The azole derivatives were more inhibitory than nonazole anti-mycotics. These anti-mycotics reduced the anti-CD3/CD28-induced mRNA expression and promoter activities for interleukin-4 and interleukin-5. The 3',5'-cyclic adenosine monophosphate analog dibutyryl 3',5'-cyclic adenosine monophosphate reversed the inhibitory effects of the anti-mycotics on interleukin-4 and interleukin-5 secretion, mRNA expression, and promoter activities. Anti-CD3/CD28 transiently (< or = 5 min) increased intracellular 3',5'-cyclic adenosine monophosphate in T cells, and the increase was greater in atopic dermatitis patients than in normal donors. The increase of 3',5'-cyclic adenosine monophosphate by anti-CD3/CD28 correlated with interleukin-4 and interleukin-5 secretion by anti-CD3/CD28. The transient 3',5'-cyclic adenosine monophosphate increase was suppressed by anti-mycotics, and azole derivatives were more suppressive than nonazoles. Azole derivatives inhibited the activity of cyclic adenosine monophosphate-synthesizing adenylate cyclase whereas terbinafine hydrochloride and tolnaftate enhanced the activity of 3',5'-cyclic adenosine monophosphate-hydrolyzing cyclic nucleotide phosphodiesterase in atopic dermatitis and normal T cells. These results suggest that the anti-mycotics may suppress interleukin-4 and interleukin-5 production by reducing 3',5'-cyclic adenosine monophosphate signal, and stress their potential use for the suppression of T helper-2-mediated allergic reactions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11886533     DOI: 10.1046/j.0022-202x.2001.01566.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

Review 1.  Severe asthma with fungal sensitization.

Authors:  Ritesh Agarwal
Journal:  Curr Allergy Asthma Rep       Date:  2011-10       Impact factor: 4.806

2.  Prophylactic efficacy of enteral miconazole administration for neonatal intestinal perforation and its potential mechanism.

Authors:  Motofumi Torikai; Satoshi Ibara; Satoshi Ieiri; Takashi Hamada; Hiroyuki Noguchi; Kazunobu Sueyoshi; Takeo Fukuda; Kazuhiro Abeyama
Journal:  Pediatr Surg Int       Date:  2016-07-29       Impact factor: 1.827

3.  Failure of itraconazole to prevent T-helper type 2 cell immune deviation: Implications for chronic rhinosinusitis.

Authors:  Joshua L Kennedy; John W Steinke; Lixia Liu; Julie Negri; Larry Borish; Spencer C Payne
Journal:  Am J Rhinol Allergy       Date:  2016-11-01       Impact factor: 2.467

4.  Peripheral blood mononuclear cells of mycetoma patients react differently to Madurella mycetomatis antigens than healthy endemic controls.

Authors:  Ehab A M Elagab; Maowia M Mukhtar; Ahmed H Fahal; Wendy W J van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2013-04-25

Review 5.  The Role of Malassezia spp. in Atopic Dermatitis.

Authors:  Martin Glatz; Philipp P Bosshard; Wolfram Hoetzenecker; Peter Schmid-Grendelmeier
Journal:  J Clin Med       Date:  2015-05-29       Impact factor: 4.241

Review 6.  Malassezia-Associated Skin Diseases, the Use of Diagnostics and Treatment.

Authors:  Ditte M L Saunte; George Gaitanis; Roderick James Hay
Journal:  Front Cell Infect Microbiol       Date:  2020-03-20       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.